{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:01:58Z","timestamp":1792098118322,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.blre.2011.01.007","type":"journal-article","created":{"date-parts":[[2011,2,27]],"date-time":"2011-02-27T14:05:40Z","timestamp":1298815540000},"page":"123-129","source":"Crossref","is-referenced-by-count":36,"title":["Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials"],"prefix":"10.1016","volume":"25","author":[{"given":"Jeremy S.","family":"Paikin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug S.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.01.007_bb0005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","author":"Mackman","year":"2008","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2011.01.007_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1538-7836.2007.02499.x","article-title":"Combined antiplatelet and anticoagulant therapy: clinical benefits and risks","author":"Eikelboom","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2011.01.007_bb0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","author":"Furie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0020","first-page":"1849","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0025","first-page":"71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2011.01.007_bb0030","first-page":"2033","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease","author":"Mehta","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2011.01.007_bb0035","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0040","first-page":"494","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0045","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0050","first-page":"1607","article-title":"Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0055","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/eurheartj\/ehp118","article-title":"Risk profile and benefits from Gp IIb\u2013IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials","author":"De Luca","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2011.01.007_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0070","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0075","first-page":"1329","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","author":"Anonymous","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0080","first-page":"1665","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","author":"ESPRIT Study Group","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0090","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2141.2009.07734.x","article-title":"Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?","author":"Karthikeyan","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.007_bb0095","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Harrington","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0100","doi-asserted-by":"crossref","first-page":"708S","DOI":"10.1378\/chest.08-0665","article-title":"Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Goodman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0105","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0110","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0115","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0120","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","article-title":"Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis","author":"Anand","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0125","first-page":"1","article-title":"The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials","author":"WAVE Investigators","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.blre.2011.01.007_bb0130","first-page":"CD001342","article-title":"Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin","author":"Algra","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2011.01.007_bb0135","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1161\/STROKEAHA.108.538157","article-title":"Anticoagulants for acute ischemic stroke","author":"Sandercock","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2011.01.007_bb0140","doi-asserted-by":"crossref","first-page":"776S","DOI":"10.1378\/chest.08-0685","article-title":"The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Becker","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0145","first-page":"1865","article-title":"Oral anticoagulant drugs","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0150","first-page":"1464","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0155","first-page":"930","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","author":"CURRENT-OASIS 7 Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"9748","key":"10.1016\/j.blre.2011.01.007_bb0160","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","article-title":"2007 Focused Update of the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee","author":"King","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2011.01.007_bb0170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.313.7058.652","article-title":"Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials","author":"Collins","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2011.01.007_bb0175","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","article-title":"Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials","author":"Eikelboom","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2011.01.007_bb0180","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.276.10.811","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0185","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0190","first-page":"561","article-title":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group","author":"Anonymous","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0195","first-page":"427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0200","first-page":"1519","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25, 307 patients","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2011.01.007_bb0215","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","author":"APPRAISE Steering Committee and Investigators","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2011.01.007_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archinte.167.2.117","article-title":"Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials","author":"Dentali","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0230","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1525-1497.2004.30419.x","article-title":"Should aspirin be continued in patients started on warfarin?","author":"Larson","year":"2004","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0240","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0022-5223(97)70264-2","article-title":"Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves","author":"Meschengieser","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.blre.2011.01.007_bb0245","first-page":"1569","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","author":"Anonymous","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0250","first-page":"1641","article-title":"C.A.S.T.: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","author":"Anonymous","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0255","first-page":"217","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","author":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0260","first-page":"633","article-title":"Adjusted-dose warfarin versus low-intensity fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","author":"Anonymous","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0265","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation","author":"Gullov","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0270","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2004.05.084","article-title":"Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study","author":"Perez-Gomez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2011.01.007_bb0275","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000047711","article-title":"Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS)","author":"Lechat","year":"2001","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.blre.2011.01.007_bb0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial","author":"van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0285","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0290","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0295","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","author":"ACTIVE Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0300","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncpcardio1372","article-title":"Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future","author":"Raju","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.blre.2011.01.007_bb0305","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","article-title":"Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents","author":"Paikin","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2011.01.007_bb0310","first-page":"1894","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2011.01.007_bb0315","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0320","first-page":"1115","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico","author":"Anonymous","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.01.007_bb0325","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","author":"Lim","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.01.007_bb0330","doi-asserted-by":"crossref","first-page":"630S","DOI":"10.1378\/chest.08-0720","article-title":"American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Albers","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.blre.2011.01.007_bb0335","doi-asserted-by":"crossref","first-page":"593S","DOI":"10.1378\/chest.08-0724","article-title":"American College of Chest Physicians. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Salem","year":"2008","journal-title":"Chest"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:02:11Z","timestamp":1740967331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0268960X11000087"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.01.007","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}